pharmaphorum4d
AbbVie launches pump-based Parkinson’s drug in EU
AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the ...
GlobalData on MSN3mon
FDA approves AbbVie’s VYALEV for advanced Parkinson’s treatment
VYALEV, also known as PRODUODOPA, is the first and only subcutaneous ... 2,400mg foslevodopa per 10ml solution dose. AbbVie ...
clinicaltrialsarena2h
7MM PD market to grow by $4.5bn between 2023 and 2033
MM PD market growth will be driven by advancements in innovative therapies, including the first DMTs, and a growing patient ...
pharmaphorum11mon
AbbVie’s 24-hour Parkinson’s therapy to roll out on NHS
Around 1,000 people with Parkinson’s disease will be able to access treatment with AbbVie’s Produodopa, the first therapy that can be delivered by a 24-hour subcutaneous infusion pump ...